A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19

Purva Patel; Monica Gaddis; Xuan Xu; Jim E Riviere; Jessica Kawakami; Emma Meyer; Majid Jaberi-Douraki; Gerald J Wyckoff

doi:10.1016/j.heliyon.2023.e13763

A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19

Heliyon. 2023 Mar;9(3):e13763. doi: 10.1016/j.heliyon.2023.e13763. Epub 2023 Feb 24.

Authors

Purva Patel¹, Monica Gaddis², Xuan Xu³, Jim E Riviere³, Jessica Kawakami¹, Emma Meyer¹, Majid Jaberi-Douraki³, Gerald J Wyckoff¹

Affiliations

¹ Division of Pharmacology and Pharmaceutical Sciences, UMKC School of Pharmacy, UMKC, Kansas City, MO, USA.
² Division of Biomedical and Health Informatics, UMKC School of Medicine, UMKC, Kansas City, MO, USA.
³ Mathematics and Data Science, Kansas State University - Olathe, Olathe, KS, USA.

Abstract

Initial studies in COVID-19 patients reported lower mortality rates associated with the use of the drug heparin, a widely used anticoagulant. The objective of this analysis was to determine whether there are adverse events associated with the administration of anticoagulants, and specifically how this might apply in patients known to have COVID-19. Data for this study were obtained from the Food and Drug Administration's Adverse Event Reporting System (FAERS) public database and from the NIH's clinical trials website. Proportional Reporting Ratios (PRR) with lower 95% confidence intervals (lower CI) and empirical Bayes geometric mean (EBGM) scores with lower 95% confidence limits were calculated for data from the FAERS database where the adverse events studied mimicked COVID-19 symptoms.

Keywords: Adverse drug events; Anticoagulants; Covid-19.